GAMMAPLEX

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Lithuania, UK.

Active ingredients

The drug GAMMAPLEX contains one active pharmaceutical ingredient (API):

1	Immunoglobulins, normal human, IV UNII 66Y330CJHS - HUMAN IMMUNOGLOBULIN G
	Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.
	Read more about Immunoglobulins, normal human, IV

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GAMMAPLEX Solution for infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BA02	Immunoglobulins, normal human, for intravascular adm.	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BA Immunoglobulins, normal human
Discover more medicines within J06BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1735343, 1735354, 1735365
GB	Medicines & Healthcare Products Regulatory Agency	171990, 172005, 217143, 375648, 375650, 375652
LT	Valstybinė vaistų kontrolės tarnyba	1089224, 1089225, 1089226
US	FDA, National Drug Code	64208-8234, 64208-8235